Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

ISMPP EU

- PMLiVE

Tagrisso tops rival drugs on survival in first-line lung cancer

Takes fight to Pfizer's Vizimpro

Bayer symbol

Bayer takes control of BlueRock stem cell joint venture

Deal values BlueRock at $1bn

- PMLiVE

ICER closely monitoring FDA’s Zolgensma investigation

Could affect initial cost assessment

- PMLiVE

Keytruda now available for untreated metastatic lung cancer patients via Cancer Drugs Fund

Proves continuing dominance in this indication

- PMLiVE

Hancock trumpets £250m fund for AI in the health service

Ties in with NHS long-term plan

- PMLiVE

DBV refiles peanut allergy immunotherapy in the US

Follows initial manufacturing concerns

- PMLiVE

Bedrock LEAPs to new heights

What do our future leaders say about LEAP?

Resonant Group

- PMLiVE

Trial backs role for Lynparza in second-line prostate cancer

Demonstrates potential significant benefit in treatment of disease

- PMLiVE

Basilea moves closer to US filing of novel antibiotic

Analysts expect US launch in 2022

- PMLiVE

2e Creative joins Fishawack Group

Strengthens global healthcare communications network

- PMLiVE

Senior leadership moves announced at Publicis Health

New roles will support European operations

Novartis day

Novartis defends Zolgensma as FDA investigates ‘data manipulation’

Gene therapy will remain on the market

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links